Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

erectile dysfunction

- PMLiVE

Roche’s Genentech and Sangamo enter neurodegenerative disease partnership worth over $1.9bn

According to WHO, neurological conditions are now the leading cause of ill health and disability worldwide

- PMLiVE

Lancet Commission report identifies two new modifiable dementia risk factors

The new risk factors identified are untreated vision loss and high low-density lipoprotein

Biogen Idec building

Biogen/Eisai’s Alzheimer’s drug shows continued cognitive improvement in long-term study

Leqembi was granted traditional US approval last year to treat patients in the early stages of the disease

- PMLiVE

Study reveals GSK’s new recombinant shingles vaccine could reduce dementia risk

Shingrix reduced dementia diagnoses by 17% compared to Merck & Co’s Zostavax after six years

- PMLiVE

NHS figures reveal record number of people in England being diagnosed with dementia

Around a third of people living with dementia in England have not received a diagnosis

- PMLiVE

AI tool better predicts progress of Alzheimer’s versus current clinical tests

The most common form of dementia accounts for up to 80% of all cases

- PMLiVE

Lexeo’s gene therapy candidate shows promise in Friedreich’s ataxia cardiomyopathy

The neurodegenerative movement disorder affects approximately one in every 40,000 people

- PMLiVE

uniQure’s investigational gene therapy shown to slow Huntington’s disease progression

The neurodegenerative disorder affects approximately 70,000 people in Europe and the US

- PMLiVE

Eli Lilly’s Alzheimer’s drug Kisunla granted FDA approval for early symptomatic disease

The amyloid plaque-targeting therapy could result in lower treatment costs and fewer infusions

- PMLiVE

Study reveals single copy of protective genetic variant delays early Alzheimer’s onset

Approximately 900,000 people in the UK are affected by dementia and Alzheimer’s is the most common form

- PMLiVE

Researchers develop AI blood test to predict Parkinson’s seven years before symptom onset

The neurodegenerative condition currently affects nearly ten million people worldwide

- PMLiVE

Roche enters licensing agreement with ALZpath to advance Alzheimer’s blood test

The agreement will leverage ALZpath’s pTau217 antibody and Roche’s Elecsys platform

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links